摘要
AIM:To investigate the relationship between loss of heterozygosity (LOH) for mannose 6-phosphate/insulin- like growth factor 2 receptor (M6P/IGF2R) and the outcomes for primary HCC patients treated with partial hepatectomy. METHODS: The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms. The patients studied were enrolled to undergo partial hepatectomy. RESULTS: M6P/IGF2R was found to be polymorphic in 73.3% (22/30) of the patients, and of these patients, 50.0% (11/22) had tumors showing LOH in M6P/IGF2R. Loss of heterozygosity in M6P/IGF2R was associated with significant reductions in the two year overall survival rate (24.9% vs 65.5%; P = 0.04) and the disease-free survival rate (17.8% vs 59.3%; P = 0.03). CONCLUSION: These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.
AIM：To investigate the relationship between loss of heterozygosity （LOH） for mannose 6-phosphate/insulin- like growth factor 2 receptor （M6P/IGF2R） and the outcomes for primary HCC patients treated with partial hepatectomy.
METHODS： The LOH for M6P/IGF2R in primary HCC patients was assessed using six different gene-specific nucleotide polymorphisms. The patients studied were enrolled to undergo partial hepatectomy.
RESULTS： M6P/IGF2R was found to be polymorphic in 73.3% （22/30） of the patients, and of these patients, 50.0% （11/22） had tumors showing LOH in M6P/IGF2R. Loss of heterozygosity in M6P/IGF2R was associated with significant reductions in the two year overall survival rate （24.9% vs 65.5%; P = 0.04） and the disease-free survival rate （17.8% vs 59.3%; P = 0.03）.
CONCLUSION： These results show M6P/IGF2R LOH predicts poor clinical outcomes in surgically resected primary HCC patients.
基金
The Special Clinical Fund of Gyeongsang National University Hospital
